CoChat

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease

Open access
McGlinchey, Aidan J., Govaere, Olivier, Geng, Dawei, Ratziu, Vlad, Allison, Michael, Bousier, Jerome, Petta, Salvatore, de Oliviera, Claudia, Bugianesi, Elisabetta, Schattenberg, Jörn M., Daly, Ann K., Hyötyläinen, Tuulia, Anstee, Quentin M., Orešič, Matej · 2022 · JHEP Reports
Cited by 105

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease with potentially severe complications including cirrhosis and hepatocellular carcinoma. Previously, we have identified circulating lipid signatures associating with liver fat content and non-alcoholic steatohepatitis (NASH). Here, we develop a metabolomic map across the NAFLD spectrum, defining interconnected metabolic signatures of steatosis (non-alcoholic fatty liver, NASH, and fibrosis). Methods: We performed mass spectrometry analysis of molecular lipids and polar metabolites in serum samples from the European NAFLD Registry patients (n = 627), representing the full spectrum of NAFLD. Using various univariate, multivariate, and machine learning statistical approaches, we interrogated metabolites across 3 clinical perspectives: steatosis, NASH, and fibrosis. Results: Following generation of the NAFLD metabolic network, we identify 15 metabolites unique to steatosis, 18 to NASH, and 15 to fibrosis, with 27 common to all. We identified that progression from F2 to F3 fibrosis coincides with a key pathophysiological transition point in disease natural history, with n = 73 metabolites altered. Conclusions: Analysis of circulating metabolites provides important insights into the metabolic changes during NAFLD progression, revealing metabolic signatures across the NAFLD spectrum and features that are specific to NAFL, NASH, and fibrosis. The F2-F3 transition marks a critical metabolic transition point in NAFLD pathogenesis, with the data pointing to the pathophysiological importance of metabolic stress and specifically oxidative stress. Clinical Trials registration: The study is registered at Clinicaltrials.gov (NCT04442334). Lay summary: Non-alcoholic fatty liver disease is characterised by the build-up of fat in the liver, which progresses to liver dysfunction, scarring, and irreversible liver failure, and is markedly increasing in its prevalence worldwide. Here, we measured lipids and other small molecules (metabolites) in the blood with the aim of providing a comprehensive molecular overview of fat build-up, liver fibrosis, and diagnosed severity. We identify a key metabolic 'watershed' in the progression of liver damage, separating severe disease from mild, and show that specific lipid and metabolite profiles can help distinguish and/or define these cases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhepr.2022.100477

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 23

  1. Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41 · DOI · Paper page
  2. Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012 · DOI · Paper page
  3. Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038/s41591-018-0104-9 · DOI · Paper page
  4. Anstee, 2020, Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort, J Hepatol, 73, 505, 10.1016/j.jhep.2020.04.003 · DOI · Paper page
  5. Orešič, 2013, Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids, Diabetologia, 56, 2266, 10.1007/s00125-013-2981-2 · DOI · Paper page
  6. Barr, 2012, Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression, J Proteome Res, 11, 2521, 10.1021/pr201223p · DOI · Paper page
  7. Vvedenskaya, 2021, Nonalcoholic fatty liver disease stratification by liver lipidomics, J Lipid Res, 62, 100104, 10.1016/j.jlr.2021.100104 · DOI
  8. Hardy, 2020, The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease, Contemp Clin Trials, 98, 106175, 10.1016/j.cct.2020.106175 · DOI · Paper page
  9. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  10. Bedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI · Paper page
  11. Pluskal, 2010, MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data, Bmc Bioinformatics, 11, 395, 10.1186/1471-2105-11-395 · DOI · Paper page
  12. Castillo, 2011, Data analysis tool for comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry, Anal Chem, 83, 3058, 10.1021/ac103308x · DOI · Paper page
  13. Aron-Wisnewsky, 2020, Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders, Nat Rev Gastroenterol Hepatol, 17, 279, 10.1038/s41575-020-0269-9 · DOI · Paper page
  14. Westerbacka, 2010, Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease, Gastroenterology, 139, 1961, 10.1053/j.gastro.2010.06.064 · DOI
  15. Burra, 2021, Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), Liver Int, 41, 1713, 10.1111/liv.14943 · DOI · Paper page
  16. Gall, 2010, alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population, PLoS One, 5, 10.1371/journal.pone.0010883 · DOI · Paper page
  17. Ferrannini, 2013, Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance, Diabetes, 62, 1730, 10.2337/db12-0707 · DOI · Paper page
  18. Dean, 2018, Structural and functional roles of ether lipids, Protein Cell, 9, 196, 10.1007/s13238-017-0423-5 · DOI · Paper page
  19. Hannich, 2020, Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients, Acta Physiol (Oxf), 232
  20. Razquin, 2018, Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial, Diabetes Care, 41, 2617, 10.2337/dc18-0840 · DOI · Paper page
  21. Suvitaival, 2018, Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men, Metabolism, 78, 1, 10.1016/j.metabol.2017.08.014 · DOI · Paper page
  22. Lemaitre, 2018, Circulating sphingolipids, insulin, HOMA-IR, and HOMA-B: the strong heart family study, Diabetes, 67, 1663, 10.2337/db17-1449 · DOI · Paper page
  23. Burla, 2018, MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines, J Lipid Res, 59, 2001, 10.1194/jlr.S087163 · DOI · Paper page

Cited by

See all 105

Metadata

Authors
McGlinchey, A. J., Govaere, O., Geng, D., Ratziu, V., Allison, M., Bousier, J., Petta, S., de Oliviera, C., Bugianesi, E., Schattenberg, J. M., Daly, A. K., Hyötyläinen, T., Anstee, Q. M., & Orešič, M.
Venue
JHEP Reports
Publisher
Elsevier BV
Published
2022-05
Volume
4
Issue
5
Pages
100477
ISSN
2589-5559 (ISSN-L)
OpenAlex
W4220707407
Cited by
105
References
15
FWCI
13.78
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • European Federation of Pharmaceutical Industries and Associations
  • European Commission (634413, 777377)
  • Innovative Medicines Initiative
  • NIHR Newcastle Biomedical Research Centre
  • Horizon 2020 Framework Programme

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1016/j.jhepr.2022.100477
The paper
McGlinchey, A. J., Govaere, O., Geng, D., Ratziu, V., Allison, M., Bousier, J., Petta, S., de Oliviera, C., Bugianesi, E., Schattenberg, J. M., Daly, A. K., Hyötyläinen, T., Anstee, Q. M., & Orešič, M. (2022). Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Reports. https://doi.org/10.1016/j.jhepr.2022.100477

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.